Job Market Relief, Biogen’s Big Bet, and Stop Trying to Beat the Market! 1/6/23
Stocks rallying after wages in December grew at a slower than expected rate. We dig into what it means for the Fed and your money. The FDA expected to decide on Biogen’s second Alzheimer’s treatment, Jefferies’ analyst Michael Yee tells us what makes this drug different than its maligned first drug Aduhelm. Plus, “A Random Walk Down Wall Street” 50 years later. Wall St. legend Burt Malkiel makes his case for passive investing and why investors shouldn’t trust historic returns…especially now.
January 6, 202344m 34s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Stocks rallying after wages in December grew at a slower than expected rate. We dig into what it means for the Fed and your money.
The FDA expected to decide on Biogen’s second Alzheimer’s treatment, Jefferies’ analyst Michael Yee tells us what makes this drug different than its maligned first drug Aduhelm.
Plus, “A Random Walk Down Wall Street” 50 years later. Wall St. legend Burt Malkiel makes his case for passive investing and why investors shouldn’t trust historic returns…especially now.
Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com
for information about our collection and use of personal data for
advertising.